Compare BON & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | QNRX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 14.5M |
| IPO Year | 2020 | 2023 |
| Metric | BON | QNRX |
|---|---|---|
| Price | $1.28 | $7.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.0K | ★ 105.1K |
| Earning Date | 01-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $390.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $5.05 |
| 52 Week High | $3.39 | $41.80 |
| Indicator | BON | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 21.97 | 43.48 |
| Support Level | $1.26 | $6.85 |
| Resistance Level | $1.58 | $9.82 |
| Average True Range (ATR) | 0.11 | 0.91 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 34.09 | 23.49 |
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.